Search Results
Our Story
Baxter touches the lives of millions of people around the world every day. Our products and therapies can be found throughout hospitals and clinics – from the ER to the OR, from the pharmacy to the ICU – as well as advancing patients’ care in their homes.
Baxter Announces Continued Growth of Pharmaceuticals Portfolio with Five Injectable Product Launches in the U.S.
Baxter International Inc. (NYSE:BAX), a global leader in injectables, anesthesia and drug compounding, today announced five new injectable pharmaceutical product launches in the U.S., joining the previous five launches announced in April of this year and marking a total of 10 U.S. injectable product launches in 2024.
Baxter Announces Definitive Agreement to Divest Its Vantive Kidney Care Segment to Carlyle for $3.8 Billion
Baxter International Inc. (NYSE:BAX), a global medtech leader, and funds managed by global investment firm Carlyle (NASDAQ:CG) today announced that they have signed a definitive agreement under which Carlyle is to acquire Baxter's Kidney Care segment, to be named Vantive, for $3.8 billion.
New Cohort Study Data Shows Baxter's Expanded Hemodialysis – Known as HDx Therapy – is Associated with Approximately 25% Lower Mortality Rate for up to Four Years
Baxter International Inc. (NYSE:BAX), a global innovator in kidney care and vital organ support, today announced new data showing expanded hemodialysis, known as HDx therapy, enabled by Theranova dialyzer, was associated with an approximately 25% lower all-cause mortality risk for up to four years when compared to high-flux hemodialysis (HF HD).
Baxter Announces Mission and Logo for Proposed Kidney Care Company Vantive
Baxter International Inc. (NYSE:BAX), a global medtech leader, announced today the mission and logo for its proposed kidney care and acute therapies company, to be named Vantive.
Baxter Secures FDA Approval of Clinolipid (Lipid Injectable Emulsion) Neonatal and Pediatric Indication
Baxter International Inc. (NYSE:BAX), a global leader in nutrition therapy, today announced U.S. FDA approval of an expanded indication for Clinolipid (Lipid Injectable Emulsion) to be used in pediatric patients, including preterm and term neonates.
Baxter Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S.
Baxter International Inc. (NYSE:BAX), a global leader in injectables, anesthesia and drug compounding, announced the continued expansion of its Pharmaceuticals portfolio with five injectable product launches in the U.S.
Baxter Reports Third-Quarter 2023 Results
Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the third quarter of 2023.
Baxter Reports Second-Quarter 2023 Results
Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the second quarter of 2023.